TenderlineUK
Procurement Intelligence
Official OCDS
Find a Tender
complete
Official procurement procedure

Provision of Testing Services and Sample Analysis

Laboratory services
UK
Published value
Not published
Submission deadline Not published
Lots published1
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: Public Health England: "Provision of Testing Services and Sample Analysis". Published status: complete. Published value: Value not published. 1 published lot. Submission deadline not published. See the official notice for participation instructions.
Contracting AuthorityPublic Health EnglandScope & CategoriesNot publishedSubmission Window
complete
No deadline published
Submission GatewayDirect notice routeLegal Basis & RegimeStandard procurementEstimated Value (exc. VAT)Not published
Bidder Intelligence · Authority Profile: Public Health England
Market Analytics
View Authority Profile →
Derived from OCDS awards & bid statistics
Published history for Public Health England. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Average Price Reduction
Not availableInsufficient comparable data
Requires at least 5 comparable procedures
Competition Density
3.3Bids / Report
71.2% of reports have one bid
Supplier ConcentrationNo estimate
Insufficient attributable awardsNo concentration estimate available
Payment Terms
Check noticePublished terms
Payment obligations depend on the applicable regime and contract. Consult the official documents.
Coverage: 58 active published awards; 52 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Price reduction compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Procedure terms
Contracting AuthorityPublic Health England
Procedure methodNot published
Procurement categoryNot published
Statuscomplete
Framework / DPSNot published
CompetitionNot published
Above thresholdNot published
Legal basisNot published
Tender period startsNot published
Clarification deadlineNot published
Electronic submissionNot published
Submission languagesNot published
Published9 Feb 2021, 22:56 GMT
Last source update9 Feb 2021, 22:56 GMT
Recurring procurementNot published
ClassificationLaboratory services
Delivery area
UK
OCIDocds-h6vhtk-0291da
What is being bought
PHE has been tasked by DHSC to urgently undertake a study to evaluate the immune response following COVID-19 vaccines as part of the National Immunisation Programme. This has been identified as a high national public health priority and a key aspect of this study requires taking 2000 samples for cellular work over a 24-month period. The UK Vaccines Taskforce have selected Oxford Immunotec as the sole supplier of T cell Testing for SARS-CoV-2 specific responses as part of the new COVID vaccine trials. Aligning PHE's study with this decision will ensure that it is consistent with the other vaccine studies performed within the UK, providing for comprehensive comparison and analysis to be carried out across all the different studies.
What changed
From the official release history
  1. Status changed to complete
    9 Feb 2021, 22:56 GMT
  2. Official notice release published
    9 Feb 2021, 22:56 GMT
  3. Buyer information updated
    9 Feb 2021, 22:56 GMT
Lots and requirements (1)
Published by the contracting authority
  • Lot 1 · #1
    Individual lot title not published
    Status not published
    Published valueNot published
    Oxford Immunotec will provide testing services and sample analysis to assist PHE in its evaluation of immune responses following COVID-19 vaccines used in the National Immunisation Programme.
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
Timeline
  1. Procedure published
    9 Feb 2021, 22:56 GMT
  2. Award active
    Not published · Not published
  3. Contract active
    Signed 9 Feb 2021, 00:00 GMT · £240,000
Commercial outcome and competition
Awards
Oxford Immunotec Ltd
Not published · Not published · active
Contracts
Contract
£240,000 · signed 9 Feb 2021, 00:00 GMT · active
Bid statisticsNo aggregate bid statistics published
Buyer and organisations in this procedure

Public Health England

Contracting authority GB-FTS-2800
View buyer profile
  • Public Health England
    buyer

    Manor Farm Road, Porton Down, Salisbury, UK, SP2 0QT
    +44 2076548000
  • High Court and Court of Appeal of England and Wales
    reviewBody

    Strand, London, WC2A 2LL
  • Oxford Immunotec Ltd
    supplier

    94C Innovation Drive,, Abingdon, UK, OX14 4RZ
Documents (0)
Official links; attachments are not copied
No data
No linked documents are published
Related procedures (0)
No data
No related procedures published
Planning and rationale
Planning budgetNot published
No-engagement rationaleNot published
Procedure rationaleThe justification to source these services from Oxford Immunotec is to enable PHE to adhere with the decision made by the UK Vaccines Taskforce who selected Oxford Immunotec as the sole supplier of T cell Testing for SARS-CoV-2 specific responses as part of the new COVID vaccine trials. Oxford Immunotec was chosen as a result of the competitive process for its expertise in T cell measurement and its unique ability to provide T-SPOT® technology, the only globally regulated ELISPOT platform - which is currently being used clinically for identifying T cells made in response to another respiratory pathogen responsible for Tuberculosis. Aligning with this verdict will ensure that the National Immunisation Programme being carried out by PHE is consistent with the other vaccine studies performed within the UK, providing for comprehensive comparison and analysis to be carried out across all the different studies. The Vaccines Taskforce has emphasised that it is important to be able to assess the different vaccines head-to-head and employing Oxford Immunotec's T-SPOT technology will measure the magnitude of the SARS-CoV-2 protein-specific T cell response of different vaccine candidates for cross-comparisons.